{"id":976543,"date":"2026-06-29T10:55:58","date_gmt":"2026-06-29T14:55:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/"},"modified":"2026-06-29T10:55:58","modified_gmt":"2026-06-29T14:55:58","slug":"tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/","title":{"rendered":"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer"},"content":{"rendered":"

\nExperienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development.<\/p>\n

\u201cWe are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through a variety of strategic clinical and corporate developments, including a background in the cell and gene therapy space,\u201d said Faraz Ali, Chief Executive Officer of Tenaya. \u201cAs Tenaya advances its genetic medicines for heart disease toward pivotal clinical trials and seeks to develop its next horizon of cardiovascular disease medicines, we expect Eric\u2019s deep expertise in finance, business development, and operations will be invaluable in creating long-term value for patients and shareholders.\u201d<\/p>\n

\u201cI am thrilled to join Tenaya at such a vital time in its evolution,\u201d said Mr. Hyllengren. \u201cWith two programs demonstrating promising safety and efficacy clinical data, a third candidate with broad potential utility poised to advance, and deep cardiovascular target discovery expertise, Tenaya is well positioned to capitalize on the opportunity to transform the treatment of heart conditions. I look forward to partnering closely with the leadership team to execute on Tenaya\u2019s strategic priorities, optimize capital allocation, and support the advancement of its promising therapies.\u201d<\/p>\n

Mr. Hyllengren brings more than two decades of experience in biotechnology finance, capital markets, and corporate strategy. He most recently served as Chief Financial Officer and Executive Vice President of Zura Bio, where he helped strengthen the company\u2019s financial position to support its clinical development programs. Prior to Zura Bio, he served as Chief Financial Officer and Chief Operating Officer at Atara Biotherapeutics, where he executed more than $500 million in public financings and guided the company through significant organizational transformation. Earlier in his career, Mr. Hyllengren held roles of increasing responsibility across finance, investor relations and business development over the course of fifteen years at Amgen.<\/p>\n

Mr. Hyllengren holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Business Administration from the University of Notre Dame.<\/p>\n

Tenaya also announced the retirement of Hiro Higa, Senior Vice President, Finance at Tenaya Therapeutics in the third quarter of 2026. Mr. Higa\u2019s retirement is unrelated to Mr. Hyllenger\u2019s hire; he will remain with Tenaya and continue to serve as a consultant to facilitate a smooth transition of the finance and accounting function.<\/p>\n

Reflecting on Mr. Hiro\u2019s departure, Mr. Ali said, \u201cDuring his six-year tenure at Tenaya, Hiro contributed significantly to the establishment of its financial infrastructure, directed all financial planning activities and played a key role in guiding Tenaya through its initial public offering. We are deeply grateful for his many contributions and wish him all the best in his retirement.\u201d<\/p>\n

\n About\u00a0Tenaya Therapeutics<\/strong>
\n
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya\u2019s pipeline includes clinical-stage candidates TN-201, a gene therapy for\u00a0MYBPC3<\/em>-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for\u00a0PKP2<\/em>-associated arrhythmogenic right ventricular cardiomyopathy (ARVC);\u00a0and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD).\u00a0Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions.\u00a0 For more information, visit\u00a0<\/strong>www.tenayatherapeutics.com<\/a>.<\/p>\n

\n Tenaya Contacts<\/strong>
\n
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com<\/u><\/a><\/p>\n

\n Investors<\/strong>
\n
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com<\/u><\/a><\/p>\n

\n Media<\/strong>
\n
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. \u201cWe are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through a variety of strategic clinical and corporate developments, including a background in the … <\/p>\n

Continue reading “Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976543","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. \u201cWe are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through a variety of strategic clinical and corporate developments, including a background in the … Continue reading "Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T14:55:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer\",\"datePublished\":\"2026-06-29T14:55:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/\"},\"wordCount\":690,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/\",\"name\":\"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=\",\"datePublished\":\"2026-06-29T14:55:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Market Newsdesk","og_description":"Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. \u201cWe are excited to welcome Eric to our leadership team as he is a highly accomplished finance executive with a proven track record of guiding organizations through a variety of strategic clinical and corporate developments, including a background in the … Continue reading \"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-29T14:55:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer","datePublished":"2026-06-29T14:55:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/"},"wordCount":690,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/","name":"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=","datePublished":"2026-06-29T14:55:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mzc2NyM3NjgxNzc1IzIyMDk0NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976543"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976543\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}